Progenics Pharmaceuticals (PGNX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
4.10 -0.43 (-9.49%) 06/19/20 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 4.10 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2019 | 12-2018 | 12-2017 | 12-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -68,552 | -67,657 | -51,013 | 10,733 | -39,119 |
| Depreciation Amortization | 2,366 | 24,697 | 1,121 | 2,078 | 565 |
| Income taxes - deferred | 6 | -1,548 | -11,435 | 1,811 | -133 |
| Accounts receivable | -12,176 | 204 | 892 | -1,322 | -3,415 |
| Other Working Capital | -14,108 | -1,955 | 234 | 6,532 | -5,996 |
| Other Operating Activity | 17,766 | -493 | 6,094 | -314 | 7,961 |
| Operating Cash Flow | $-74,698 | $-46,752 | $-54,107 | $19,518 | $-40,137 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -7,231 | -817 | -232 | -3,939 | -322 |
| Net Acquisitions | -8,000 | N/A | N/A | N/A | -6,202 |
| Other Investing Activity | -277 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | $-15,508 | $-817 | $-232 | $-3,939 | $-6,524 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 48,650 | N/A |
| Debt Repayment | -5,843 | -5,390 | N/A | N/A | N/A |
| Common Stock Issued | 1,942 | 100,107 | 5,495 | 1,340 | 1,737 |
| Other Financing Activity | 0 | 0 | 15 | -368 | -292 |
| Financing Cash Flow | $-3,901 | $94,717 | $5,510 | $49,622 | $1,445 |
| Exchange Rate Effect | -48 | -92 | 83 | -86 | 17 |
| Beginning Cash Position | 139,220 | 92,164 | 140,910 | 75,795 | 119,302 |
| End Cash Position | 45,065 | 139,220 | 92,164 | 140,910 | 74,103 |
| Net Cash Flow | $-94,155 | $47,056 | $-48,746 | $65,115 | $-45,199 |
| Free Cash Flow | |||||
| Operating Cash Flow | -74,698 | -46,752 | -54,107 | 19,518 | -40,137 |
| Capital Expenditure | -7,231 | -817 | -269 | -4,286 | -370 |
| Free Cash Flow | -81,929 | -47,569 | -54,376 | 15,232 | -40,507 |